Q1 EPS Forecast for Janux Therapeutics Decreased by Analyst

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Research analysts at HC Wainwright decreased their Q1 2025 EPS estimates for shares of Janux Therapeutics in a research note issued on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.48) for the quarter, down from their previous forecast of ($0.46). HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Janux Therapeutics' Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $2.82 EPS.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

JANX has been the subject of several other reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Wedbush reiterated an "outperform" rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Leerink Partnrs upgraded shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday, November 22nd. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, Leerink Partners lifted their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $88.00.

Remove Ads

Janux Therapeutics Trading Down 1.4 %

Shares of JANX traded down $0.42 during trading hours on Thursday, reaching $30.22. The stock had a trading volume of 859,554 shares, compared to its average volume of 818,445. The firm has a 50-day simple moving average of $41.27 and a 200 day simple moving average of $47.50. Janux Therapeutics has a 12 month low of $29.54 and a 12 month high of $71.71. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -25.83 and a beta of 3.23.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 13,334 shares of the business's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. This trade represents a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 50,002 shares of company stock worth $2,684,703 over the last quarter. 29.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in JANX. RA Capital Management L.P. raised its holdings in shares of Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock valued at $554,977,000 after acquiring an additional 1,200,000 shares in the last quarter. FMR LLC increased its position in shares of Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock worth $464,189,000 after purchasing an additional 845,266 shares during the last quarter. Janus Henderson Group PLC raised its stake in Janux Therapeutics by 41.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock valued at $190,617,000 after purchasing an additional 1,038,996 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its position in Janux Therapeutics by 46.5% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock valued at $188,246,000 after purchasing an additional 1,115,412 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in Janux Therapeutics by 47.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after buying an additional 986,750 shares in the last quarter. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.